Provided by Tiger Trade Technology Pte. Ltd.

Humacyte, Inc.

0.5790
-0.0159-2.67%
Pre-market: 0.58310.0041+0.71%08:13 EDT
Volume:2.92M
Turnover:1.71M
Market Cap:160.96M
PE:-1.16
High:0.6000
Open:0.5905
Low:0.5751
Close:0.5949
52wk High:2.55
52wk Low:0.5261
Shares:278.00M
Float Shares:245.00M
Volume Ratio:0.49
T/O Rate:1.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4975
EPS(LYR):-0.2582
ROE:-547.87%
ROA:-49.87%
PB:5.15
PE(LYR):-2.24

Loading ...

Humacyte - Enters Underwriting Agreement for Underwritten Offering on June 10, 2026 - SEC Filing

THOMSON REUTERS
·
Jun 12

Humacyte Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jun 11

Humacyte, Inc. : H.c. Wainwright Raises Target Price to $4 From $3

THOMSON REUTERS
·
Jun 11

BUZZ-U.S. STOCKS ON THE MOVE-Enliven Therapeutics, DXC Technology, Humacyte

Reuters
·
Jun 11

U.S. RESEARCH ROUNDUP-Arthur J. Gallagher & Co, Datadog, Oracle

Reuters
·
Jun 11

Humacyte prices 47,619,048-share follow-on offering at $1.05 each to raise $50 million

Reuters
·
Jun 11

Humacyte - Prices Public Offering of 47.62 Mln Shares at $1.05 per Share

THOMSON REUTERS
·
Jun 11

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

GlobeNewswire
·
Jun 11

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

Dow Jones
·
Jun 11

Humacyte's Bioengineered Blood Vessel Hits Primary Endpoint in Phase 3 Trial

Dow Jones
·
Jun 11

Humacyte Says ATEV Met Late-Stage Study Endpoint in Interim Analysis, Launches Public Offering; Shares Fall

MT Newswires Live
·
Jun 11

BRIEF-Humacyte, Inc. Announces Proposed Public Offering Of Common Stock

Reuters
·
Jun 11

Humacyte announces V012 study of ATEV meets primary endpoint

TIPRANKS
·
Jun 11

Humacyte announces common stock offering, no amount given

TIPRANKS
·
Jun 11

Humacyte launches underwritten follow-on common stock offering

Reuters
·
Jun 11

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

THOMSON REUTERS
·
Jun 11

Humacyte - to Use Net Proceeds for Symvess Commercialization and Pipeline Development

THOMSON REUTERS
·
Jun 11

Humacyte ATEV beats AV fistula on catheter-free days in interim Phase 3 V012 trial in female dialysis patients

Reuters
·
Jun 11

Humacyte Atev Met Superiority Primary Endpoint Compared to Standard of Care Av Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients

THOMSON REUTERS
·
Jun 11

Humacyte - Study Enrollment to Terminate After Meeting Primary Endpoint

THOMSON REUTERS
·
Jun 11